nach oben

Current Bladder Dysfunction Reports

Erschienen in:

30.03.2016 | BPH-Related Voiding Dysfunction (R Lee, Section Editor)

An Outcomes Review of Minimally Invasive Transurethral Convective Water Vapor Energy (WAVE) Therapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

verfasst von: Neal D. Shore

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

The Rezūm® System utilizing convective water vapor energy (WAVE™) has been proven to safely and effectively ablate obstructive tissue of the prostate, including the median lobe. Clinical trials have demonstrated rapid and significant relief of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) while improving quality of life scores. Moreover, durability of these beneficial results has been demonstrated through 12 months of follow-up. The most common side effects include dysuria, urgency, and hematuria, which are typically of short duration. Importantly, erectile and ejaculatory functions are preserved. This thermal therapy can be performed in an outpatient or office setting under oral sedation, prostate block, or conscious IV sedation.

Verhamme KMC et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care—the triumph project. Eur Urol. 2002;42(4):323–8.CrossRefPubMed

Roehrborn CG. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol. 2008;10(1):14–25.PubMedPubMedCentral

Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173(4):1256–61.CrossRefPubMed

Hollingsworth JM, Wilt TJ. Lower urinary tract symptoms in men. Br Med J. 2014;349:g4474. doi:10.1136/bmj.g4474.

Rosen R et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637–49.CrossRefPubMed

Rom M et al. Lower urinary tract symptoms and depression. BJU Int. 2012;110(11c):E918–21.CrossRefPubMed

Speakman M et al. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)—focus on the UK. BJU Int. 2015;115(4):508–19.CrossRefPubMed

Bautista OM et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials. 2003;24(2):224–43.CrossRefPubMed

Kaplan SA, Lee JY, Meehan AG et al. Time course of incident adverse experiences associated with doxazosin, finasteride, and combination therapy in men with benign prostatic hyperplasia: the medical therapy of prostatic symptoms (MTOPS) trial. J Urol. 2015. doi:10.1016/j.juro.2015.11.065.

10.

McConnell JD et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98.CrossRefPubMed

11.

Verhamme KMC et al. Treatment strategies, patterns of drug use and treatment discontinuation in men with luts suggestive of benign prostatic hyperplasia: the triumph project. Eur Urol. 2003;44(5):539–45.CrossRefPubMed

12.

Rassweiler J et al. Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol. 2006;50(5):969–80.CrossRefPubMed

13.

Reich O et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180(1):246–9.CrossRefPubMed

14.

Tang Y et al. Bipolar transurethral resection versus monopolar transurethral resection for benign prostatic hypertrophy: a systematic review and meta-analysis. J Endourol. 2014;28(9):1107–14.CrossRefPubMedPubMedCentral

15.

McVary KT, et al. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH). American Urological Association Education and Research, Inc.; 2010. (https://www.auanet.org/education/guidelines/benign-prostatic-hyperplasia.cfm).

16.

Barry MJ et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care. 1995;33(4):AS145–55.PubMed

17.

Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7 Suppl 9:S3–14.PubMedPubMedCentral

18.

Rosen RC, Cappelleri JC, Gendrano N. The international index of erectile function (IIEF): a state-of-the-science review. Int J Impot Res. 2002;14(4):226–44.CrossRefPubMed

19.

Rosen RC et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 2000;11(6):319–26.CrossRef

20.

Rosen RC et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822–30.CrossRefPubMed

21.•

Dixon CM et al. Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezūm(®) system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol. 2015;7:13–8. This article is important because it was the first study to establish the acute ablative capabilities using the Rezūm® system in the treatment of benign prostatic hyperplasia. It provides the histologic and MRI evidence of the necrosis of the ablated lesions.

22.•

Mynderse LA et al. Rezūm system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology. 2015;86(1):122–7. This research is important because it was the first study to evaluate by MRI the physical effects, through 6 months, of convective thermal energy transfer with water vapor as a means of treating lower urinary tract symptoms due to benign prostatic hyperplasia.

23.••

Dixon CM, Cedano ER, Pacik D et al. Efficacy and safety of Rezum system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urol. 2015;86:1042–47. This paper is very important because it examines the safety and efficacy of the Rezūm® System over a 12-month follow-up period. It provides data from a series of pilot studies performed at multiple institutions in three countries which demonstrates the treatment efficacy and positive safety profile for this new method of treating LUTS secondary to BPH.

24.••

McVary KT, Gange, SN, Gittelman MC et al. Minimally invasive prostate convective water vapor energy (WAVE) ablation: A multicenter, randomized, controlled study for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2015. doi:10.1016/j.juro.2015.10.181. This paper is very important because it is the first multicenter, randomized controlled study among 197 patients randomized to convective water vapor energy (WAVE) ablation or control and followed over 12 months. It demonstrates treatment efficacy across multiple treatment end points as well as its safety profile.

Titel: An Outcomes Review of Minimally Invasive Transurethral Convective Water Vapor Energy (WAVE) Therapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
verfasst von: Neal D. Shore
Publikationsdatum: 30.03.2016
Verlag: Springer US
Erschienen in: Current Bladder Dysfunction Reports / Ausgabe 2/2016
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-016-0363-6

Neu im Fachgebiet Urologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

An Outcomes Review of Minimally Invasive Transurethral Convective Water Vapor Energy (WAVE) Therapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Abstract

Neu im Fachgebiet Urologie

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Ureterstriktur: Innovative OP-Technik bewährt sich

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Urologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

The Devastated Bladder Outlet in Cancer Survivors After Local Therapy for Prostate Cancer

Long-Term Urologic Evaluation Following Spinal Cord Injury

Complex Fistula Disease in the Pelvic Malignancy Cancer Survivor Who Has Been Treated with Radiation

Evaluation and Management of Mid-Urethral Sling Complications

Neuromodulation for Pelvic Pain and Sexual Dysfunction

Influence of Age and Obesity on 5α-Reductase 2 Gene Expression

Neu im Fachgebiet Urologie

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Ureterstriktur: Innovative OP-Technik bewährt sich

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Urologie